Skip to main content

Table 1 Expression levels of six potential biomarkers in patients with high-risk prostate cancer who underwent radical prostatectomy with and without neoadjuvant treatment

From: Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

     NNA NHT CHT p-value p value (NNA vs. CHT) p value (NHT vs. CHT)
AR Epithelial cells Nuclear Area 3.01 ± 0.10 2.06 ± 0.13 2.07 ± 0.0.06 < 0.001 < 0.001 0.984
   Intensity 2.27 ± 0.08 1.94 ± 0.12 1.79 ± 0.05 < 0.001 < 0.001 0.208
   Immunoreactivity score 7.20 ± 0.39 4.50 ± 0.40 4.16 ± 0.18 < 0.001 < 0.001 0.441
  Cytoplasmic Potitive/Negative (% of positive) 60/22 (73.2%) 48/16 (75.0%) 82/162 (33.6%) < 0.001 < 0.001 < 0.001
Stromal cells   Area 1.21 ± 0.65 1.72 ± 0.81 1.55 ± 0.64 < 0.001 < 0.001 0.077
   Intensity 1.08 ± 0.06 1.50 ± 0.08 1.33 ± 0.04 < 0.001 < 0.001 0.034
   Immunoreactivity score 1.54 ± 0.14 2.94 ± 0.24 2.26 ± 0.10 < 0.001 < 0.001 0.010
GR Epithelial cells Nuclear Area 1.80 ± 0.10 1.69 ± 0.13 2.36 ± 0.05 < 0.001 < 0.001 < 0.001
   Intensity 1.55 ± 0.10 1.66 ± 0.12 1.88 ± 0.06 0.009 0.004 0.076
   Immunoreactivity score 3.35 ± 0.29 3.38 ± 0.37 4.83 ± 0.20 < 0.001 < 0.001 0.001
  Cytoplasmic Potitive/Negative (% of positive) 0/80 (0%) 0/64 (0%) 38/196 (16.2%) < 0.001 < 0.001 0.001
Stromal cells   Area 1.92 ± 0.07 1.78 ± 0.06 1.77 ± 0.05 0.180 0.055 0.875
   Intensity 2.82 ± 0.02 2.88 ± 0.04 2.92 ± 0.03 0.133 0.049 0.396
   Immunoreactivity score 5.41 ± 0.20 5.13 ± 0.19 5.23 ± 0.14 0.663 0.452 0.672
ERα Stromal cells Nuclear Area 0.73 ± 0.08 1.13 ± 0.11 1.24 ± 007 < 0.001 < 0.001 0.392
   Intensity 0.65 ± 0.07 1.19 ± 0.12 1.32 ± 0.07 < 0.001 < 0.001 0.391
   Immunoreactivity score 0.85 ± 0.11 1.97 ± 0.25 2.51 ± 0.17 < 0.001 < 0.001 0.074
PR Epithelial cells Cytoplasmic Area 0.82 ± 0.08 0.28 ± 0.07 0.30 ± 0.04 < 0.001 < 0.001 0.808
   Intensity 1.54 ± 0.14 0.38 ± 0.09 0.52 ± 0.06 < 0.001 < 0.001 0.197
   Immunoreactivity score 1.82 ± 0.20 0.50 ± 0.14 0.63 ± 0.08 < 0.001 < 0.001 0.455
Stromal cells Nuclear Area 1.13 ± 0.06 1.56 ± 0.09 2.30 ± 0.04 < 0.001 < 0.001 < 0.001
   Intensity 2.24 ± 0.11 2.47 ± 0.09 2.94 ± 0.02 < 0.001 < 0.001 < 0.001
   Immunoreactivity score 2.85 ± 0.19 3.75 ± 0.24 6.76 ± 0.14 < 0.001 < 0.001 < 0.001
MOB4A Epithelial cells Cytoplasmic Area 2.21 ± 0.13 2.06 ± 0.15 2.63 ± 0.05 < 0.001 0.002 0.001
   Intensity 1.09 ± 0.08 1.20 ± 0.11 1.49 ± 0.04 < 0.001 < 0.001 0.014
   Immunoreactivity score 2.93 ± 0.24 3.20 ± 0.31 4.09 ± 0.13 < 0.001 < 0.001 0.004
YAP1 Epithelial cells Nuclear Area 1.54 ± 0.09 1.27 ± 0.15 1.76 ± 0.06 < 0.001 0.048 0.002
   Intensity 1.68 ± 0.11 1.27 ± 0.15 1.78 ± 0.05 < 0.001 0.377 0.002
   Immunoreactivity score 3.03 ± 0.24 2.83 ± 0.42 3.55 ± 0.17 0.086 0.104 0.113
  Cytoplasmic Area 1.95 ± 0.12 1.73 ± 0.14 2.42 ± 0.06 < 0.001 < 0.001 < 0.001
   Intensity 1.14 ± 0.05 1.23 ± 0.08 1.73 ± 0.11 < 0.001 < 0.001 < 0.001
   Immunoreactivity score 2.57 ± 0.26 2.90 ± 0.32 4.71 ± 0.20 < 0.001 < 0.001 < 0.001
  1. NNA no neoadjuvant threatment, NHT neoadjuvant hormonal therapy, CHT neoadjuvant chemohormonal therapy, AR androgen receptor, GR glucocorticoid receptor, ER estrogen receptor, PR progesterone receptor